









BMJ Open Interventions for the management of post-COVID-19 condition (long COVID): protocol for a living systematic review and network meta-analysis

Dena Zeraatkar,^{1,2} Michael Ling,¹ Sarah Kirsh ,² Tanvir Jassal,¹ Tyler Pitre ,³ Samantha Chakraborty ,⁴ Tari Turner ,⁴ Lyn Turkstra,⁵ Roger S McIntyre,⁶ Ariel Izcovich ,⁷ Lawrence Mbuagbaw ,² Thomas Agoritsas,^{2,8,9} Signe A Flottorp ,¹⁰ Paul Garner,¹¹ Rachel J Couban,¹ Jason W Busse ^{1,2}

To cite: Zeraatkar D, Ling M, Kirsh S, *et al*. Interventions for the management of post-COVID-19 condition (long COVID): protocol for a living systematic review and network meta-analysis. *BMJ Open* 2025;**15**:e086407. doi:10.1136/bmjopen-2024-086407

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2024-086407>).

Received 13 March 2024
Accepted 01 November 2024



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Dena Zeraatkar;
zeraatd@mcmaster.ca

ABSTRACT

Background Up to 15% of survivors of COVID-19 infection experience long-term health effects, including fatigue, myalgia and impaired cognitive function, termed post-COVID-19 condition or long COVID. Several trials that study the benefits and harms of various interventions to manage long COVID have been published and hundreds more are planned or are ongoing. Trustworthy systematic reviews that clarify the benefits and harms of interventions are critical to promote evidence-based practice.

Objective To create and maintain a living systematic review and network meta-analysis addressing the benefits and harms of pharmacologic and non-pharmacologic interventions for the treatment and management of long COVID.

Methods Eligible trials will randomise adults with long COVID to pharmacologic or non-pharmacologic interventions, placebo, sham or usual care. We will identify eligible studies by searching MEDLINE, EMBASE, CINAHL, PsycINFO, AMED and CENTRAL from inception, without language restrictions.

Reviewers will work independently and in duplicate to screen search records, collect data from eligible trials, including trial and patient characteristics and outcomes of interest and assess risk of bias. Our outcomes of interest will include patient-reported fatigue, pain, postexertional malaise, changes in education or employment status, cognitive function, mental health, dyspnoea, quality of life, physical function, recovery and serious adverse events. For each outcome, when possible, we will perform a frequentist random-effects network meta-analysis. When there are compelling reasons to suspect that certain interventions are only applicable or effective for a subtype of long COVID, we will perform separate network meta-analyses. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach will guide our assessment of the certainty of evidence.

We will update our living review biannually, on the publication of a seminal trial, or when new evidence emerges that may change clinical practice.

Conclusion This living systematic review and network meta-analysis will provide comprehensive, trustworthy and up-to-date summaries of the evidence addressing the

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Our review will use a broad search strategy and inclusion criteria, consider outcomes reflecting the values and preferences of patients, screen studies and extract data in duplicate to reduce the opportunity for errors and evaluate the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.
- ⇒ Despite our comprehensive search strategy, it is possible we will not identify all eligible randomised trials.
- ⇒ We have made certain methodological decisions to ensure the feasibility of the review.

benefits and harms of interventions for the treatment and management of long COVID. We will make our findings available publicly and work with guideline-producing organisations to inform their recommendations.

Ethics and dissemination The study describes the protocol for a systematic review that uses data from published trial reports. Therefore, the study is exempt from ethics review. We intend to deposit all data in a public repository and publish each iteration of the living review online.

BACKGROUND

The COVID-19 pandemic produced a global health crisis, affecting millions worldwide and causing significant health and economic consequences.^{1 2} The prevalence of long COVID is difficult to establish, given most symptoms are non-specific, and many studies lack sufficiently rigorous designs to confidently attribute symptoms to COVID-19 infection.^{3 4} Nonetheless, evidence suggests that up to 15% of survivors may experience long-term health effects, including fatigue, myalgia and impaired cognitive function—termed post-COVID-19 condition or long COVID.^{5–14}



The best available evidence suggests that approximately 6%–7% of adults in the general population are affected by long COVID.^{15–19}

The aetiology of long COVID remains unclear and investigators have proposed several potential causes including viral persistence, autoimmunity, ‘microclots’ and psychological mechanisms.²⁰ There is heterogeneity in the definition of long COVID and some evidence indicates it may comprise several distinct phenotypes.²¹ Risk factors include female sex, comorbidities and patient-reported psychological distress.^{22–24} Conversely, severity of acute COVID-19 infection does not appear to predict long COVID and even non-hospitalised patients with mild infections are susceptible.²⁵ Symptoms of long COVID may persist following acute infection or may relapse and remit.²⁶ Evidence on the long-term trajectory of the condition is limited but existing studies suggest that most patients experience a significant reduction of symptoms at 1 year following the initial acute infection.²⁷

There is considerable overlap of signs, symptoms and medical history between long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).²⁸ For example, ME/CFS often emerges following viral infections, similar to long COVID that emerges following infection with SARS-CoV-2.²⁸ Notably, approximately half of patients diagnosed with long COVID also meet criteria for ME/CFS.^{29–31}

Considerable resources have been invested to study long COVID, including US\$1 billion by the US National Institutes of Health (NIH).³² In August 2023, the NIH established the Office of Long COVID Research and Practice and launched a suite of clinical trials investigating treatments, including five adaptive platform trials—trials that compare several interventions simultaneously with the option to add or remove interventions based on emerging evidence.^{33 34}

Several trials testing interventions for the management of long COVID have been published to date^{35–38} and hundreds more are planned or ongoing.^{39–41} These trials, however, will be published faster than evidence users, such as clinicians and patients, can read or make sense of them and will come with strengths and limitations that may not be immediately apparent.

Ongoing discourse in the literature shows there is uncertainty about optimal management of long COVID.^{42–44} In the absence of trustworthy summaries of the evidence, patients living with long COVID are receiving unproven treatments—many of which are costly and some of which may be harmful.^{42–46} For interventions for which trials have been published, for example, trials testing physical rehabilitation and cognitive behavioural therapy, patients and healthcare providers have questioned their credibility.^{47–49} Trustworthy systematic reviews that clarify the benefits and harms of available interventions are critical to promote evidence-based care of patients.

We present a protocol for a living systematic review and network meta-analysis of all pharmacologic and non-pharmacologic interventions for long COVID. Unlike

a traditional systematic review that is only up-to-date at a single point in time, we will update this living review as new evidence emerges.^{50 51} This review will provide comprehensive, trustworthy and up-to-date summaries of the evidence addressing interventions for the management of long COVID.

We anticipate that the living systematic review and network meta-analysis will become a trusted reference point for clinicians, patients and national and international professional associations and authoritative organisations that intend to produce guideline recommendations on the treatment and management of long COVID. We have already engaged a committee of evidence users, including healthcare professionals and guideline-producing organisations, in the design of this initiative. This committee will frequently be asked for feedback on our methods and the presentation of our results, to ensure that our products align with their needs. We hope that our findings will expedite the identification of the most effective interventions for patients with long COVID and inform future guideline development efforts.

METHODS

We report our protocol according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for protocols.^{52 53}

The initial search for this systematic review was conducted in December 2023, with the first publication anticipated in November 2024. The review will be updated every 6 months, with funding secured to support updates for 3 years, until December 2026.

Eligibility criteria

Eligible studies will randomise adults with long COVID, defined by WHO as symptoms 3 or more months following laboratory-confirmed, probable or suspected COVID-19 infection that persist for at least 2 months, to pharmacological or non-pharmacological interventions, placebo, sham, usual care or alternative pharmacological or non-pharmacological interventions, with no restrictions on the date or language of publication.²⁶ This definition, although broad, is consistent with the most recent definition published by the National Academies of Sciences, Engineering, and Medicine and reflects the limitations in current scientific knowledge about long COVID.^{54 55}

Given the diverse manifestations of long COVID, our review will not further restrict eligibility based on diagnostic criteria.²⁶ However, subgroup analyses will test how diagnostic criteria influence the effectiveness of interventions.

We anticipate that trials will largely include patients who meet the WHO criteria for long COVID but some trials may not report the time since the acute COVID-19 infection or the duration of long COVID symptoms. We will include such trials in our primary analysis but will also perform additional sensitivity analyses excluding these trials to test the robustness of our findings.

Based on empirical evidence that preprint and published reports of randomised trials generally provide consistent results,^{56–58} we will include both preprint and published trial reports, but will also perform sensitivity analyses excluding preprints.^{56 59}

At this time, there is too little known about long COVID to anticipate which interventions may be effective. Trials are investigating many types of interventions, including drugs (eg, colchicine, sulodexide, beta-blockers), behavioural and physical therapies (eg, cognitive behavioural therapy, aerobic exercise training), dietary supplements and medical devices (transcranial direct current stimulation).^{33 40 60 61} We will not restrict eligibility based on the type of intervention and anticipate including trials addressing a diverse range of therapies.

We will exclude pseudorandomised trials, trials involving animals, trials investigating treatments for acute COVID-19, trials testing interventions to prevent long COVID and trials including patients who do not meet criteria for long COVID.^{26 62} We will also exclude randomised trials with fewer than 25 participants in each arm. We anticipate that smaller trials are unlikely to meaningfully contribute to meta-analyses, are more likely to include unrepresentative samples and arms that are prognostically imbalanced and are at higher risk of publication bias.⁶³

While there are hundreds of long COVID trials underway, trials have progressed at a slower pace than anticipated.⁶⁴ Depending on feasibility, for select interventions of high potential interest to evidence users, in the first year of the living systematic review, we will consider including indirect evidence from trials addressing interventions for ME/CFS. Clinical experts and evidence users will help determine whether to include this indirect evidence. Subgroup analyses will investigate differences between the effects of interventions between long COVID and ME/CFS. If we find evidence of inconsistency, we will only present results of trials addressing long COVID. Similar to long COVID, we will include trials that recruit patients according to published diagnostic criteria for

ME/CFS but perform subgroup analyses investigating potential differences in the effects of interventions based on these diagnostic criteria. Table 1 lists our eligibility criteria.

Data sources and search strategy

An experienced medical research librarian developed a comprehensive search strategy for MEDLINE, EMBASE, CINAHL, PsycINFO, AMED, CENTRAL and preprint servers (MedRxiv and ResearchSquare), from inception. Our search strategy (online supplemental file 1) combines terms related to long COVID with a filter for randomised trials. Additionally, we plan to supplement our search using the Epistemonikos COVID-19 Repository—a living catalogue of COVID-19 research—and by reviewing the references of relevant systematic reviews.^{37 40 65}

The medical research librarian will update the searches at minimum biannually to facilitate biannual updates of the living review. We aim to update the search no more than 3 months before the publication of each iteration of the review.

To ensure our review remains up-to-date, for select interventions identified by our network of evidence users as highly important with great potential for efficacy, we will integrate methods for prospective systematic reviews—systematic reviews that include unpublished and interim data from ongoing and completed trials.⁶⁶ During the COVID-19 pandemic, trialists reported trouble publishing trials due to null results, inability to achieve the target sample size and diminishing interest from journals. In response, the WHO REACT Working Group performed prospective systematic reviews for select topics.^{67 68} These reviews sourced ongoing trials via trial registries and invited trialists to share their interim or completed data. This model proved successful and also mitigated the influence of publication bias on review results.^{67 68} We plan to emulate a similar model for critical interventions of long COVID. Our experience with other living systematic reviews and the experience of other

Table 1 Eligibility criteria

Category	Inclusion criteria	Exclusion criteria
Population	<ul style="list-style-type: none"> ▶ Adults (aged 18 years or older) or trials in which results are presented stratified according to age or trials in which 80% or more of participants are adults ▶ Post-COVID-19 condition, defined as symptoms (eg, fatigue, shortness of breath, cognitive dysfunction) that last for at least 2 months and that occur or persist 3 or more months following laboratory-confirmed, probable or suspected COVID-19 infection and that cannot be explained by an alternative diagnosis 	<ul style="list-style-type: none"> ▶ Children (aged <18 years of age) ▶ Adults or children whose symptoms have not lasted at least 2 months or whose symptoms have not occurred or persisted for at least 3 months since confirmed, probable or suspected acute COVID-19 ▶ Studies involving animals ▶ Studies addressing treatments for acute COVID-19 or interventions for the prevention of long COVID ▶ Trials of fewer than 25 participants per arm
Interventions	<ul style="list-style-type: none"> ▶ Any pharmacological or non-pharmacological intervention, standard care or placebo 	
Study design	<ul style="list-style-type: none"> ▶ Randomised trial ▶ Published trial report ▶ Preprint trial report ▶ Conference abstracts describing a randomised trial ▶ Registrations of eligible trials with or without results ▶ Published in any language 	<ul style="list-style-type: none"> ▶ Published or preprint trial protocols ▶ Pseudorandomised trials



research groups suggest that some trial groups are receptive to sharing unpublished trial data.^{67–69}

For interventions for which we consider evidence from ME/CFS trials, we will work with an experienced research medical librarian to devise additional search strategies specific to the interventions for which we will consider indirect evidence.

Study selection

Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers will work independently and in duplicate to screen the titles and abstracts of search records and subsequently the full-texts of records deemed partially eligible at the title and abstracts screening stage using Covidence (<https://www.covidence.org>), an online systematic review software for screening titles and abstracts and full-text articles. Reviewers will resolve disagreements by discussion, or, if necessary, through adjudication by a third reviewer.

Data extraction

Following training and calibration exercises to ensure sufficient agreement, pairs of reviewers will work independently and in duplicate to collect data from eligible trials using a pilot-tested data collection form in an Excel spreadsheet (Microsoft Office Excel 2019). Reviewers will resolve disagreements by discussion or by consultation with a third reviewer, if necessary.

Reviewers will collect data on trial characteristics (eg, trial design, country of origin, funding, diagnostic criteria for long COVID), patient characteristics (eg, age, sex and gender, employment and education status, receipt of COVID-19 vaccination, method of acute COVID-19 diagnosis, severity of acute COVID-19 infection, duration of long COVID, number of infections, equity-related characteristics, long COVID symptoms), characteristics of interventions and comparators (eg, type of intervention, treatment duration) and patient-important outcomes.

For dichotomous outcomes, reviewers will extract the number of patients and events in each arm, and, for continuous outcomes, the number of patients, a measure of central tendency (mean or median) and a

measure of variability (eg, SD, SE, 95% CI, p value) for each arm. For continuous outcomes, reviewers will prioritise extracting changes in the outcome from baseline, and if not reported, the outcome at follow-up. For each outcome, reviewers will preferentially extract the results from intention-to-treat analyses without any imputations for missing data.⁷⁰

We will also prioritise outcome data at the longest reported timepoint at which the intervention is still being administered to allow for potential cumulative effects of interventions to emerge without effects dissipating due to termination of the intervention. When trials report data at timepoints at which the intervention is no longer being administered but randomised groups are still maintained, we will consult experts who are blind to the results of the trial about the duration of time the interventions being tested are expected to exert effects. If appropriate, we will consider extracting and analysing data at the longest reported point of follow-up even if the intervention is no longer administered. We anticipate that rehabilitation and behavioural interventions are designed to teach patients coping mechanisms they can independently apply after completing the programme and so results at the longest follow-up may better reflect the sustained effects of the intervention.

Our outcomes of interest are informed by a published core outcome set for long COVID and will include at a minimum fatigue, pain, postexertional malaise, changes in education or employment status, cognitive function, mental health, dyspnoea, quality of life, patient-reported physical function, recovery and serious adverse events (as defined by each trial).^{71 72} We will extract data for all validated instruments measuring our outcomes of interest. **Table 2** presents examples. We will re-evaluate and potentially revise our choice of outcomes annually by discussion with patient partners and knowledge users and by considering emerging evidence. If we find important reasons to include additional outcomes, we will revisit previously included trials to collect data on these additional outcomes.

Table 2 Example of eligible instruments for outcomes of interest

Fatigue	Modified Fatigue Impact Scale ¹⁴⁸ ; Fatigue Assessment Scale ¹⁴⁹ ; Multidimensional Fatigue Inventory ¹⁵⁰ ; Chalder Fatigue Questionnaire ¹⁵¹ ; Checklist Individual Strength Fatigue Subscale ¹⁵²
Pain severity	Visual Analogue Scale ¹⁵³ ; Numerical Rating Scale; Brief Pain Inventory (severity subscale) ¹⁵⁴ ; McGill Pain Questionnaire ¹⁵⁵
Postexertional malaise	DePaul Symptom Questionnaire ¹⁵⁶ ; DePaul Post-Exertional Malaise Questionnaire ¹⁵⁷
Cognitive function	Digit Symbol Substitution Test ¹⁵⁸ ; Behaviour Rating Inventory of Executive Function—Adult Version (BRIEF-A) ¹⁵⁹
Mental health	SF-36 (mental health) ¹⁶⁰ ; SF-36 (mental component summary) ¹⁶⁰ ; Hospital Anxiety and Depression Scale ¹⁶¹ ; Hamilton Anxiety Rating Scale ¹⁶² ; Hamilton Depression Rating Scale ¹⁶³ ; Beck Depression Inventory ¹⁶⁴
Dyspnoea	Modified Medical Research Council Dyspnoea Scale ¹⁶⁵
Quality of life	EuroQol-5D ¹⁶⁶ ; SF-36 ¹⁶⁰ ; WHO Quality of Life Questionnaire ¹⁶⁷
Physical function	SF-36 (physical functioning) ¹⁶⁰ ; SF-36 (physical component summary) ¹⁶⁰
EuroQol-5D, EuroQol 5 Dimension; SF-36, 36-item short-form.	

Given the relapse and remission patterns associated with long COVID and the potential for interventions to have long-term effects, for crossover trials, we will only collect data for the first phase of the trial before washout and crossover.

For trials initially available as a preprint that are subsequently published, we will rely on the results of the published trial report unless the preprint reports additional outcome data not included in the published trial report.

In response to growing concerns about the prevalence of potentially fabricated or falsified research,^{73 74} reviewers will use the Trustworthiness in RAndomised Clinical Trials (TRACT) checklist to evaluate each trial for the risk of data falsification, fabrication or major errors in the conduct of the trial or analysis of data that could seriously undermine trial conclusions.⁷⁵ This checklist includes 19 items in seven domains (governance, author group, plausibility of intervention, timeframe, dropouts, baseline characteristics and outcomes) addressing the integrity and trustworthiness of trials. Each item is rated as no concerns, some concerns and major concerns.

The checklist does not include a cut-off at which a trial is considered suspicious and there is currently limited experience using the checklist in systematic reviews. Therefore, the authorship group will discuss all trials that are flagged as raising concerns for one or more domains. We will perform sensitivity analyses excluding trials that are deemed suspicious. We are also aware of another instrument to assess the risk of falsified or fabricated data in trials currently under development (INSPECT-SR).⁷⁶ On its publication, we will evaluate the instrument and consider integrating it into our workflow, either as a replacement for or in addition to the TRACT checklist.

We anticipate that the effects of interventions may depend on diagnostic criteria for long COVID or ME/CFS, severity of acute COVID-19, time since infection, number of infections, vaccination status and SARS-CoV-2 variant.²² When reported, we will extract stratified data based on these factors to facilitate subgroup analyses.

Risk of bias assessment

Following training and calibration, reviewers will work independently and in duplicate to assess risk of bias (RoB) using a modified version of the Cochrane-endorsed RoB 2.0 tool—the gold standard for assessing limitations in trials that may bias results.⁷⁷ The RoB 2.0 assesses the RoB across five domains: bias due to randomisation (eg, random sequence generation, allocation concealment), bias due to deviations from the intended intervention (eg, lack of blinding leading to imbalances in co-interventions across trial arms), bias due to missing outcome data (eg, attrition), bias due to measurement of the outcome (eg, unblinded outcome assessment) and selective reporting (eg, selective reporting of outcome measures based on results).

To assess the RoB due to deviations from the intended intervention, we will consider the effect of assignment

rather than adherence to the intervention—since this effect is likely to be the observed effect in clinical settings and of the greatest interest to evidence users. Our modified version of the tool includes the same domains, but with revised response options (ie, definitely low RoB, probably low RoB, probably high RoB and definitely high RoB) and guidance tailored to issues relevant for the present review (eg, removing guidance for assessing RoB of adhering to the intervention, listing important cointerventions).

Unless we encounter compelling reasons to do otherwise, we will consider trials without blinding of patients, healthcare providers and investigators at high RoB due to deviations from intended intervention. This decision is based on the potential for unequal distribution of potentially effective cointerventions (eg, physical activity, social engagement, energy management) across trial arms. We will make an exception for trials that compare two or more interventions that are matched in terms of the level of interaction between trial participants and healthcare providers.^{78 79} Patients might expect interventions with higher levels of interaction to be more effective, potentially influencing their perception of outcomes and their likelihood of pursuing additional beneficial activities. When interventions are matched in terms of interaction, patients are less likely to have strong preconceptions about their comparative effectiveness.

Reviewers will resolve disagreements by discussion or by consultation with a third reviewer, if necessary.

Data synthesis and analysis

To describe trials and participants, we will present descriptive characteristics. Means and medians and associated measures of variability (eg, 95% CI, SD) will describe continuous variables and counts and proportions dichotomous and categorical variables.

Given the heterogeneity in the definition of long COVID and evidence indicating that it may comprise several distinct phenotypes,²¹ we anticipate that some interventions may be better suited for patients with certain phenotypes of long COVID. For example, pulmonary rehabilitation will likely only be effective for patients who are experiencing pulmonary sequelae related to COVID-19,⁸⁰ and interventions targeting cognitive function will likely only be effective for patients experiencing neurocognitive sequelae related to COVID-19.⁸¹ Other interventions may be suitable for patients experiencing general symptoms related to long COVID, such as fatigue, postexertional malaise and headaches. We will perform separate syntheses when there are compelling clinical reasons to suspect that certain interventions are only applicable or effective for a subtype of long COVID. Clinical experts in our authorship group will lead these decisions and regularly revisit them based on new evidence.

To summarise the comparative benefits and harms of interventions, we will perform network and pairwise meta-analyses. Network meta-analyses compare three or more interventions, grouped into nodes, by pooling



direct and indirect evidence.⁶⁶ To facilitate network meta-analysis, we will classify interventions into ‘nodes’ considering the drug class for pharmacological interventions, class of therapy (eg, cognitive behavioural therapy, aerobic exercise) for behavioural and physical interventions and characteristics of the therapy for other non-pharmacological interventions. If we find evidence that the effects of interventions are different based on their mode (group vs individual, online or in-person), intensity or dose of delivery, we will create separate nodes. We will group placebo and sham interventions and standard care in the same node unless there is evidence that suggests that there are differences in the effect of interventions when compared against placebo/sham and standard care.⁷⁸

We anticipate that trials may measure the same constructs using different instruments. To enhance interpretation, reviewers may convert effects measured by different instruments assessing the same construct into the most commonly used or familiar instrument.^{82 83} We will avoid converting effects across instruments due to potential differences in the range of constructs covered by each instrument. We will also avoid standardised mean differences due to their potential to be influenced by differences in variability across trial populations.⁸³

For each outcome and outcome measure, random-effects network meta-analysis using a frequentist framework with the restricted maximum likelihood (REML) heterogeneity estimator—a conservative approach to network meta-analysis—will be used to pool the results of trials.^{84 85} Our choice of a frequentist over a Bayesian framework is motivated by evidence that there are seldom important differences between the results of Bayesian and frequentist networks and the computational complexity associated with analysing large networks under a Bayesian framework.⁸⁴

Relative risks (RRs) will summarise the results of dichotomous outcomes—except for serious adverse events that will be summarised using risk differences due to the propensity for trials to frequently report zero events, precluding calculation of RRs and ORs—and mean differences for continuous outcomes, along with associated 95% CIs. When network meta-analysis is not possible, we will perform pairwise random-effects meta-analysis with the REML heterogeneity estimator.⁸⁵

We will use I^2 statistics to summarise the magnitude of heterogeneity in meta-analyses and interpret an I^2 value of 0%–40% as not important, 30%–60% as moderate heterogeneity, 50%–90% as substantial heterogeneity and 75%–100% as considerable heterogeneity.^{86 87} The I^2 value, however, is prone to misinterpretation since even small degrees of unimportant inconsistency may translate to high I^2 values if estimates from studies are highly precise.^{88 89} Hence, we will also consider the absolute magnitude of differences in effect estimates across studies. For analyses that include 10 or more studies, we will test for publication bias using Egger’s test and qualitatively review funnel plots for evidence of asymmetry.^{90 91}

A feature of network meta-analyses is their ability to generate treatment rankings but we will avoid using treatment rankings to interpret our results based on theoretical and empirical considerations that they may be misleading.^{92–94}

Diverse trial outcomes or outcome measures may lead to disconnected networks or preclude network formation. In such situations, consistent with established guidance, we will present the results of disconnected networks separately.⁶⁶ We will refrain from model-based approaches to link networks because of their novelty and limited evidence supporting their reliability.⁹⁵ If networks cannot be formed, we will present pairwise meta-analyses. With the emergence of more trial evidence, we anticipate that disconnected networks will eventually combine to become connected.

To enhance interpretability of results, we will transform relative effects (eg, RRs) to absolute effects (eg, number of events per 1000 patients), using the median risk of the outcome reported across the control groups of eligible trials.⁹⁶

We will test for incoherence using node-splitting.⁹⁷ In case of incoherence, we will investigate potential sources considering our a priori defined hypotheses for effect modification: diagnostic criteria for long COVID, time since infection, number of infections, vaccination status, severity of acute COVID-19 and SARS-CoV-2 variant.²² Should we choose to include evidence from ME/CFS trials, we will also consider ME/CFS as a potential source of incoherence. In the event that tests for effect modification are unable to identify a credible source of incoherence, we will downgrade the certainty of evidence. Conversely, if we confidently identify the source of incoherence, we will perform separate analyses stratified by the source of incoherence.

We have also generated similar a priori factors to explain potential heterogeneity in results between trials: diagnostic criteria for long COVID, time since infection, number of infections, vaccination status, severity of acute COVID-19 and SARS-CoV-2 variant.^{22 98} Meta-regressions and subgroup analyses will test for subgroup effects based on these factors. Notably, we will avoid pooling trials rated at low and high RoB indiscriminately. Instead, we will test for differences between the results of these trials, and when we detect important differences, rely on trials at low RoB. If we choose to include evidence from ME/CFS trials, we will also perform subgroup analyses comparing the results of trials addressing long COVID and ME/CFS. Inferences of subgroup effects often prove spurious.^{99–108}

Such spurious claims may be attributed to testing many factors, leading to apparent but inaccurate evidence of effect modification due to chance, selective reporting or improper statistical analysis.^{108–114} To avoid misleading claims, we will assess the credibility of subgroup effects using the ICEMAN tool—the gold standard tool for evaluating effect modification in trials and systematic reviews.¹¹⁵

We will perform all analyses using the *meta* and *netmeta* packages in R (V.4.1.2, Vienna, Austria) and make all

code to reproduce our results freely accessible on Open Science Framework.^{116 117}

Certainty of evidence and reporting

Results from studies may appear impressive, but we may have low confidence in results due to limitations of the evidence. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach will guide our assessment of the certainty (quality) of evidence.^{118–120} The GRADE approach rates the certainty of evidence as either high, moderate, low or very low certainty based on considerations of RoB (ie, study limitations), inconsistency (ie, heterogeneity in results between trials), indirectness (ie, differences between the questions addressed in studies and the question of interest), publication bias (ie, the tendency for studies with statistically significant results or positive results to be published, published faster or published in journals with higher visibility), imprecision (ie, random error), intransitivity (ie, violation of joint randomisability) and incoherence (ie, differences between direct and indirect estimates). High certainty evidence indicates situations in which we are confident that the estimated effect represents the true effect and low or very low certainty evidence indicates situations in which the estimated effect may be substantially different from the true effect.

A minimally contextualised approach will guide our judgements related to imprecision.¹²¹ The minimally contextualised approach does not consider statistical significance as the only indicator of whether an intervention is effective. An estimate may not be statistically significant but may still have evidence of moderate certainty for benefit or harm. Conversely, an intervention may produce results that are statistically significant but that indicate no important benefit or harm. The minimally contextualised approach considers only whether the effect estimates exceed the minimum important difference (MID)—the smallest difference in an outcome that patients find important—and does not consider whether the effect is small, moderate or large. If the point estimate meets or exceeds the MID, we will assess the certainty of there being an effect and use the null as the threshold for judgements about imprecision. If the point estimate falls below the MID, we will assess the certainty in the absence of an important effect, and downgrade the certainty if the confidence interval crosses the MID, indicating that the intervention may potentially confer an important effect.

We will source MIDs either from the literature, or, when not available, survey our review authors and patient partners. MIDs of patient-reported outcomes are typically determined either using anchor-based or distribution-based methods.¹²² Anchor-based methods use an external ‘anchor’ to interpret the magnitude of change in a measure or outcome. Distribution-based methods rely on the distribution of the data to interpret the importance of change in a measure. We will prioritise anchor-based MIDs over distribution-based MIDs, since anchor-based estimates reflect patients’ direct experiences. We anticipate

that guideline producing organisations will fully contextualise the results to formulate recommendations.¹²³ Finally, should a published MID be unavailable for any of the outcomes of interest, particularly for dichotomous outcomes like recovery and return to work/education for which MIDs are typically not derived, we will survey patient partners and our partner evidence users on reasonable ranges using a previously established procedure.¹²⁴

To make judgements about intransitivity, we will consider the potential effect modifiers within the network, including the credibility of effect modification, the strength of effect modification and the distribution of effect modifiers across direct comparisons. There is currently limited evidence on potential effect modifiers of interventions for long COVID. We anticipate that the effects of interventions may vary based on diagnostic criteria, severity of acute COVID-19, time since infection, number of infections, vaccination status and SARS-CoV-2 variant. If we find credible evidence of effect modification based on these or other factors, we will consider rating down for intransitivity when appropriate. For comparisons that include evidence from ME/CFS trials, we will additionally rate down for indirectness.

Reporting of results

We will report our living review according to the PRISMA checklist for network meta-analyses and PRISMA extension for living systematic reviews.^{52 53 125} PRISMA flow diagrams will illustrate the total number of search records, the number of records excluded, reasons for exclusion and the total number of trials included in the review. Network and forest plots will present network geometry and results from meta-analyses, respectively. GRADE Evidence Profiles will summarise effect estimates and the certainty of evidence.⁹⁶

We will describe our results using GRADE plain language summaries (ie, describing high certainty evidence with declarative statements, moderate certainty evidence with ‘probably’, low certainty evidence with ‘may’ and very low with ‘very uncertain’).¹²⁶

For each outcome, we will place interventions in categories from best to worst.^{127 128} First, we will classify interventions according to whether they are more or less effective than placebo or standard care. If the treatment effect of the intervention vs placebo or standard care is less than the MID, the intervention will remain in the same group as placebo or standard care. If, on the other hand, the effect meets or exceeds MID, the intervention can be classified as more or less effective than placebo or standard care, depending on the direction of the effect. Subsequently, we will compare the interventions classified as more effective than placebo or standard care against each other by examining whether the differences in effects between them exceed the MID. In the final step, we will further categorise interventions according to the certainty of evidence.

Each iteration of the living review will also be accompanied by a plain language summary (each <800 words)



that describe our findings in lay language for healthcare providers and patients who may not be familiar with network meta-analysis methods. We will draft these summaries according to established guidance by Cochrane: they will describe the types of interventions tested and describe the benefits and harms of interventions supported by moderate or high certainty evidence.⁶⁶ We anticipate these plain language summaries will reduce the opportunity for misinterpretation of our findings by healthcare providers, patients and other decision-makers who may not be familiar with network meta-analysis methods or the interpretation of evidence according to the GRADE approach.

Updating and triggers for retirement

We will update our living systematic review and network meta-analysis every 6 months or sooner in the event of publication of practice-changing evidence (eg, publication of a seminal trial, when the certainty of evidence or the magnitude or direction of the effect of an intervention importantly changes). Preprints and journal publications will communicate the results of each iteration of our review. This approach adheres to best practices in updating living reviews: it balances the need for up-to-date evidence with the time needed to ensure that the review is sufficiently rigorous, focuses our efforts on disseminating critical findings and maximises the feasibility of the project.^{50 129}

We will retire our living systematic review when the evidence base becomes stable with few to no new trials, if we reach high or moderate certainty evidence for all interventions and outcomes suggesting that new evidence is unlikely to change current estimates, when our network of evidence users suggest that the findings of the living systematic review are no longer relevant to them, if we deplete our funding, or if we can no longer maintain the personnel needed to continue the living review.¹³⁰ At this time, given the timeline of planned trials and the funding available to us, we intend to continue to maintain the living systematic review for 3 years.^{33 34}

Our Open Science Framework repository dedicated to the living review will inform evidence users of the status of the review (whether it is active or retired), the anticipated date of the next update and the results of the most recent iteration of the review (osf.io/9h7zm).

Conflicts of interest

Systematic reviews necessitate subjective judgements about the magnitudes of benefits and harms of interventions and the certainty of evidence. To ensure such judgements are not unduly influenced, we will screen all coauthors and members of our team for financial and intellectual conflicts of interest using a standardised procedure developed by the *BMJ*.¹³¹

Financial conflicts will include stocks, grants, research contracts, royalties and speaking fees and travel accommodations and intellectual conflicts will include academic publications or statements on social or traditional media

that could make reviewers attached to a particular intervention or point of view. We will exclude individuals with financial conflicts and restrict intellectual conflicts to no more than 25% of the team. Only reviewers completely free of both financial and intellectual conflicts of interest will be involved with screening search records, data extraction, RoB assessments, data analysis and assessment of the certainty of evidence.

Patient and public involvement

As part of our funding application, patients were involved from the study's inception, reviewing and offering feedback on the protocol, provided by the Long Covid Web Patient Advisory Council.

When interpreting our results, we will rely on patients' judgements about whether they consider benefits of a particular therapy to outweigh harms. To do this, we will perform semi-structured interviews and discussions with purposively selected groups of patient partners, aiming for diversity in demographics (eg, age, sex, under-represented racial or ethnic groups, income, abilities) and experiences of long COVID (eg, severity, duration). These interviews will be intended to offer explanations for why certain therapies may be preferential to others. This feedback ensures that this study directly aligns with patient priorities.

For each iteration of the review, three to four patient partners will also review plain language summaries that describe our findings using language that will be accessible to the general public for readability and acceptability.^{132 133} Patients will be involved in dissemination of results to ensure accessibility.

We anticipate that this living systematic review will become a trusted reference point for national and international professional associations and authoritative organisations that intend to produce guideline recommendations on the management of long COVID. We will prioritise engaging organisations that involve patients in their guideline development process and consider patient values and preferences—consistent with standards for producing trustworthy guidelines.^{134–137}

ETHICS AND DISSEMINATION

This study describes the protocol for a systematic review that uses data from published trial reports. Therefore, the study is exempt from ethics review. While we have involved patients in the design of this review and intend to involve them in the interpretation of our findings, patients will act in the capacity of colleagues and co-investigators, which consistent with Canadian guidance, precludes the need for formal review from an institutional research ethics board.¹³⁸ We intend to deposit all data in a public repository and publish each iteration of the living review online.

DISCUSSION

Our living systematic review and network meta-analysis will provide comprehensive, trustworthy and up-to-date

summaries of the evidence addressing interventions for the management of long COVID. We expect to produce at minimum six iterations of this living review. We hope that our findings will accelerate the identification of effective interventions for patients with long COVID.

To our knowledge, this is the first living network meta-analysis investigating the benefits and harms of pharmacological and non-pharmacological interventions for long COVID. Discussions with our network and searches of research databases confirm that the proposed review is original and there are no existing reviews of the same scope or rigour as we propose. The Canadian Agency for Drugs and Technologies in Health living review only provides a descriptive summary of trials, without quantitative synthesis or rigorous appraisal.³⁴ Other living reviews addressing long COVID do not focus on interventions for management of the condition, perform network meta-analysis or assess the certainty of evidence.¹³⁰

We anticipate that this living systematic review will become a trusted reference point for clinicians, patients and national and international professional associations and authoritative organisations that intend to produce guideline recommendations on the treatment and management of long COVID. We invite guideline producing organisations that are either publishing or planning clinical practice guidelines addressing long COVID to join our committee of evidence users, who inform the type of data that we collect and our methodological approaches to ensure that our products align with their needs. Our model of simultaneously providing trustworthy summaries of evidence to several guideline developing organisations will prove more efficient than each organisation performing its own overlapping evidence syntheses and optimise the translation of research into clinical practice.

We also invite clinical trialists to share interim or completed trial data for inclusion in our living systematic review. We are especially interested in trials that may not be published due to null findings, insufficient sample sizes or lack of interest from journals—trials at risk of the ‘file drawer’ effect. Sharing these data helps prevent publication bias and honours the commitment of trial participants, funders and investigators by ensuring that their efforts improve patient care.

Strengths and limitations

Strengths of this living systematic review and network meta-analysis include a broad search strategy and inclusion criteria, consideration of outcomes of interest reflecting the values and preferences of patients, screening of studies and extraction of data in duplicate to reduce the opportunity for errors,^{139–144} application of GRADE to evaluate the certainty of evidence and commitment to data sharing and open science practices.¹⁴⁵

We also acknowledge potential limitations. First, despite our comprehensive search strategy, it is possible we will not identify all eligible randomised trials. To mitigate this issue, we will supplement our search with

the Epistemonikos COVID-19 repository, which independently performs searches and screens for relevant randomised trials.⁶⁵

Second, while there are many trials underway, trials have progressed at a slower pace than anticipated.⁶⁴ Our ongoing surveillance of trial registries has identified over 200 eligible trials, indicating that considerable evidence is forthcoming. For example, the US RECOVER programme includes five adaptive platform trials.¹⁴⁶ In 2023, Canada funded a US\$20 million research network, called Long Covid Web, which is also anticipated to support clinical trials.¹⁴⁷ Furthermore, RECLAIM, the Canadian platform trial investigating interventions for long COVID, will also contribute evidence for several therapeutic interventions. Our plan to integrate methods for prospective systematic reviews will also ensure that there will be sufficient data to make a living review both feasible and valuable for evidence users.

Third, there is heterogeneity in the definition of long COVID and some evidence suggests that it may comprise several distinct phenotypes. The heterogeneous nature of long COVID, along with the absence of an objective universally accepted diagnostic tool, may influence the interpretability and applicability of our results. We will address this by conducting subgroup analyses based on diagnostic criteria for long COVID, severity of acute COVID-19, time since infection, number of infections, vaccination status and SARS-CoV-2 variant. If sensitive and specific biomarker tests or updated diagnostic criteria for long COVID emerge during our living systematic review, we will restrict future iterations to studies applying these new methods. However, we acknowledge that the current lack of such diagnostic tools remains a limitation and challenge for management of patients.

Finally, we have made certain methodological decisions, choices regarding the design and procedures of our review, to ensure the feasibility of our living systematic review. One methodological decision is our approach to evaluating the RoB due to missing outcome data. We plan to assess the RoB due to missing outcome data by considering the proportion of participants with missing outcome data, reasons for missingness and whether missing data could importantly influence the effect estimate. An alternative approach to assessing RoB due to missing outcome data involves imputing missing data across a range of plausible scenarios and making a judgement based on the robustness of the results to imputation.⁷⁰ This approach, however, is also impractical due to the anticipated numbers of outcomes and comparisons in the living systematic review and network meta-analysis.

Likewise, to inform judgements about the importance of effect estimates, we intend to perform pragmatic searches of Google Scholar to inform reasonable ranges of MIDs. While systematic searches for MIDs may offer a more comprehensive overview of MID estimates, performing these systematic searches for all measurement instruments would compromise our ability to perform timely



updates of the review. We believe the proposed methods strike a reasonable balance between rigour and feasibility.

Conclusion

This protocol describes the planned methods of a living systematic review and network meta-analysis addressing the comparative effectiveness of interventions for the management of long COVID. We anticipate that our findings will inform clinical practice, clinical practice guidelines and guide the investigation of promising interventions for future trials.

Author affiliations

¹Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada

²Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

³Division of Respiriology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

⁴School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia

⁵School of Rehabilitation Science and Program in Neuroscience, McMaster University, Hamilton, Ontario, Canada

⁶Department of Psychiatry and Pharmacology, University of Toronto, Toronto, Ontario, Canada

⁷Department of Medicine, Universidad del Salvador, Buenos Aires, Argentina

⁸Division General Internal Medicine, Department of Medicine, University Hospitals of Geneva, Geneva, Switzerland

⁹The MAGIC Evidence Ecosystem Foundation, Oslo, Norway

¹⁰Centre for Epidemic Interventions Research, Norwegian Institute of Public Health, Oslo, Norway

¹¹Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK

X Samantha Chakraborty @SamanthaC_22, Ariel Izcovich @izcovichA, Thomas Agoritsas @ThomasAgoritsas, Signe A Flottorp @SFlottorp and Jason W Busse @JasonWBusse

Contributors DZ and JWB conceived the idea for the study. RJC devised and performed literature searches. DZ wrote the first draft of the manuscript, and all authors reviewed the manuscript and approved the final version. DZ managed the project. DZ acted as the guarantor for the overall content of the manuscript.

Funding This research was funded in part by the Long Covid Web and the Canadian Institutes of Health Research (518846). JWB is supported, in part, by a Canadian Institutes of Health Research Canada Research Chair in the prevention and management of chronic pain.

Disclaimer The funders had no role in developing the study design or in the collection, analysis, interpretation of data, writing of the report or decision to submit the article for publication.

Competing interests RSM has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatrix, AbbVie and Atai Life Sciences. RSM is a CEO of Braxia Scientific.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the 'Methods' section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability

of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Sarah Kirsh <http://orcid.org/0009-0001-1271-8509>

Tyler Pitre <http://orcid.org/0000-0003-3015-0723>

Samantha Chakraborty <http://orcid.org/0000-0002-9708-4532>

Tari Turner <http://orcid.org/0000-0002-7990-1623>

Ariel Izcovich <http://orcid.org/0000-0001-9053-4396>

Lawrence Mbuagbaw <http://orcid.org/0000-0001-5855-5461>

Signe A Flottorp <http://orcid.org/0000-0003-2961-7461>

Jason W Busse <http://orcid.org/0000-0002-0178-8712>

REFERENCES

- 1 Pannee S, Kantamaneni K, Palaniswamy U, *et al*. Health, Economic and Social Development Challenges of the COVID-19 Pandemic: Strategies for Multiple and Interconnected Issues. *Healthcare (Basel)* 2022;10:770.
- 2 Delardas O, Kechagias KS, Pontikos PN, *et al*. Socio-Economic Impacts and Challenges of the Coronavirus Pandemic (COVID-19): An Updated Review. *Sustainability* 2022;14:9699.
- 3 Haslam A, Prasad V. Comparability of Control and Comparison Groups in Studies Assessing Long COVID. *Am J Med* 2023.
- 4 Tracy Beth H, Shamez L, Vinay P. How methodological pitfalls have created widespread misunderstanding about long COVID. *BMJ Evid Based Med* 2023.
- 5 Chen C, Haupt SR, Zimmermann L, *et al*. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis* 2022;226:1593–607.
- 6 Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw Open* 2021;4:e2111417.
- 7 Perlis RH, Lunz Trujillo K, Safarpour A, *et al*. Association of Post-COVID-19 Condition Symptoms and Employment Status. *JAMA Netw Open* 2023;6:e2256152.
- 8 Wulf Hanson S, Abbafati C, Aerts JG, *et al*. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022;328:1604.
- 9 Carfi A, Bernabei R, Landi F, *et al*. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;324:603–5.
- 10 Xiong Q, Xu M, Li J, *et al*. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. *Clin Microbiol Infect* 2021;27:89–95.
- 11 Goërtz YMJ, Van Herck M, Delbressine JM, *et al*. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res* 2020;6:00542–2020.
- 12 Nehme M, Brailard O, Alcoba G, *et al*. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. *Ann Intern Med* 2021;174:M20-5926:723–5.
- 13 Perlis RH, Santillana M, Ognyanova K, *et al*. Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA Netw Open* 2022;5:e2238804.
- 14 Ceban F, Ling S, Lui LMW, *et al*. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. *Brain Behav Immun* 2022;101:93–135.
- 15 Ford ND, Agedew A, Dalton AF, *et al*. Notes from the Field: Long COVID Prevalence Among Adults - United States, 2022. *MMWR Morb Mortal Wkly Rep* 2024;73:135–6.
- 16 Fang Z, Ahrensbrak R, Rekito A. Evidence Mounts That About 7% of US Adults Have Had Long COVID. *JAMA* 2024;332:5–6.
- 17 National Center for Health Statistics. Household pulse survey. CDC. n.d. Available: <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>
- 18 UK Office of National Statistics. Prevalence of ongoing symptoms following coronavirus (covid-19) infection in the UK. 2023. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/>

- healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/30march2023/ [Accessed 30 Mar 2023].
- 19 Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. *Nat Med* 2024;30:2148–64.
 - 20 Turner S, Khan MA, Putrino D, et al. Long COVID: pathophysiological factors and abnormalities of coagulation. *Trends Endocrinol Metab* 2023;34:321–44.
 - 21 Reese JT, Blau H, Casiraghi E, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. *EBioMedicine* 2023;87:104413.
 - 22 Maglietta G, Diodati F, Puntoni M, et al. Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. *J Clin Med* 2022;11:1541.
 - 23 Notarte KI, de Oliveira MHS, Peligro PJ, et al. Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. *J Clin Med* 2022;11:7314.
 - 24 Wang S, Quan L, Chavarro JE, et al. Associations of Depression, Anxiety, Worry, Perceived Stress, and Loneliness Prior to Infection With Risk of Post-COVID-19 Conditions. *JAMA Psychiatry* 2022;79:1081–91.
 - 25 Matta J, Wiernik E, Robineau O, et al. Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. *JAMA Intern Med* 2022;182:19.
 - 26 Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis* 2022;22:e102–7.
 - 27 Fumagalli C, Zocchi C, Tassetti L, et al. Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phone-based interview follow-up cohort study. *Eur J Intern Med* 2022;97:36–41.
 - 28 Komaroff AL, Lipkin WI. ME/CFS and Long COVID share similar symptoms and biological abnormalities: road map to the literature. *Front Med (Lausanne)* 2023;10:1187163.
 - 29 Bonilla H, Quach TC, Tiwari A, et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome is common in post-acute sequelae of SARS-CoV-2 infection (PASC): Results from a post-COVID-19 multidisciplinary clinic. *Front Neurol* 2023;14:1090747.
 - 30 Twomey R, DeMars J, Franklin K, et al. Chronic Fatigue and Postexertional Malaise in People Living With Long COVID: An Observational Study. *Phys Ther* 2022;102:pzac005.
 - 31 Kedor C, Freitag H, Meyer-Arndt L, et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. *Nat Commun* 2022;13:5104.
 - 32 Subbaraman N. US health agency will invest \$1 billion to investigate 'long COVID. *Nat New Biol* 2021;591:356.
 - 33 Harris E. Federal Government Announces Long COVID Trials, Research Office. *JAMA* 2023;330:797.
 - 34 Pitre T, Cheng S, Cusano E, et al. Methodology and design of platform trials: a meta-epidemiological study. *J Clin Epidemiol* 2023;157:1–12.
 - 35 Hansen KS, Mogensen TH, Agergaard J, et al. High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial. *Lancet Reg Health Eur* 2023;24:100539.
 - 36 Spencer LH, Hendry A, Mankuola A, et al. What interventions or best practice are there to support people with long covid, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review. *Health Policy* [Preprint].
 - 37 Veronese N, Bonica R, Cotugno S, et al. Interventions for Improving Long COVID-19 Symptomatology: A Systematic Review. *Viruses* 2022;14:1863.
 - 38 Bramante C, Buse JB, Liebovitz D, et al. Outpatient treatment of covid-19 and the development of long covid over 10 months: a multi-center, quadruple-blind, parallel group randomized phase 3 trial. Available: <https://ssrn.com/abstract=4375620> or <http://dx.doi.org/10.2139/ssrn.4375620> [Accessed 7 Mar 2022].
 - 39 Chao Y-S, Vu T, McGill SC, et al. Clinical Classification and Interventions for Post-COVID-19 Condition: A Scoping Review. *cjht* 2022;2.
 - 40 Chee YJ, Fan BE, Young BE, et al. Clinical trials on the pharmacological treatment of long COVID: A systematic review. *J Med Virol* 2023;95:e28289.
 - 41 Ledford H. Long-COVID treatments: why the world is still waiting. *Nature New Biol* 2022;608:258–60.
 - 42 Davies M. Long covid patients travel abroad for expensive and experimental “blood washing.” *BMJ* 2022;378:1671.
 - 43 Ladyzhets B. Underwhelming: NIH trials fail to test meaningful long covid treatments — after 2.5 years and \$1 billion. *Stat News*; 2023.
 - 44 Sellers F. Desperate covid long-haulers turn to costly, unproven treatments: washington post. 2022. Available: <https://www.washingtonpost.com/health/2022/11/25/long-covid-treatmentsunproven-brain-fog/>
 - 45 Belluck P. Paxlovid may reduce risk of long covid in eligible patients, study finds. *The NYT*; 2022. Available: <https://www.nytimes.com/2022/11/07/health/paxlovid-long-covid.html?smid=tw-share>
 - 46 Califf DR. And preliminary epidemiological findings point to the distinct possibility of the bivalent vaccines and antivirals reducing risk of long covid. *TWIT*; 2022. Available: https://twitter.com/DrCaliff_FDA/status/1592269459133431809?s=20
 - 47 Wilson C. Exercise programme helps people with long covid, but it's no panacea. 2024.
 - 48 Tuller D. Trial by error: dutch CBT study for long covid proves that unblinded studies with subjective outcomes generate positive reports: virology; 2023. 2023. Available: <https://virology.ws/2023/05/25/trial-by-error-dutch-cbt-study-for-long-covid-reports-proves-thatunblinded-studies-with-subjective-outcomes-produce-positive-results-as-predicted/>
 - 49 Vink M, Vink-Niese A. Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. *Healthcare (Basel)* 2020;8:552.
 - 50 Elliott JH, Synnot A, Turner T, et al. Living systematic review: 1. Introduction—the why, what, when, and how. *J Clin Epidemiol* 2017;91:23–30.
 - 51 Elliott JH, Turner T, Clavisi O, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. *PLoS Med* 2014;11:e1001603.
 - 52 Hutton B, Salanti G, Caldwell DM, et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. *Ann Intern Med* 2015;162:777–84.
 - 53 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:71.
 - 54 National Academies of Sciences E, Medicine. *A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences*. Washington, DC: The National Academies Press, 2024:186.
 - 55 Ely EW, Brown LM, Fineberg HV. National Academies of Sciences, Engineering, and Medicine Committee on Examining the Working Definition for Long Covid. *Long Covid Defined N Engl J Med* 2024.
 - 56 Zeraatkar D, Pitre T, Leung G, et al. Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. *bmjmed* 2022;1:e000309.
 - 57 Davidson M, Evrenoglou T, Graña C, et al. Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials. *BMC Med Res Methodol* 2024;24:9.
 - 58 Janda G, Khetpal V, Shi X, et al. Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles. *JAMA Netw Open* 2022;5:e2245847.
 - 59 Weibel S, Popp M, Reis S, et al. Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis. *Res Synth Methods* 2023;14:357–69.
 - 60 Kuut TA, Müller F, Aldenkamp A, et al. A randomised controlled trial testing the efficacy of Fit after COVID, a cognitive behavioural therapy targeting severe post-infectious fatigue following COVID-19 (ReCOVer): study protocol. *Trials* 2021;22:867.
 - 61 Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol* 2023;21:133–46.
 - 62 Thawethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. *JAMA* 2023;329:1934–46.
 - 63 Dickersin K, Min Yi. Publication bias: the problem that won't go away. *Ann N Y Acad Sci* 1993;703:135–46; .
 - 64 Wadman M. Long Covid is a 'national crisis.' So why are grants taking so long to get. *Science* 2022;376:1262–3.
 - 65 Verdugo-Paiva F, Vergara C, Ávila C, et al. COVID-19 Living Overview of Evidence repository is highly comprehensive and can be used as a single source for COVID-19 studies. *J Clin Epidemiol* 2022;149:195–202.
 - 66 Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions* version 6.3. 2022. Available: www.training.cochrane.org/handbook

- 67 Shankar-Hari M, Vale CL, *et al.* Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. *JAMA* 2020;326:499–518.
- 68 Sterne JAC, Murthy S, Diaz JV, *et al.* Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19. *JAMA* 2020;324:1330.
- 69 Siemieniuk RA, Bartoszko JJ, Zeraatkar D, *et al.* Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ* 2020;370:m2980.
- 70 Guyatt GH, Ebrahim S, Alonso-Coello P, *et al.* GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. *J Clin Epidemiol* 2017;87:14–22.
- 71 Munblit D, Nicholson TR, Needham DM, *et al.* Studying the post-COVID-19 condition: research challenges, strategies, and importance of Core Outcome Set development. *BMC Med* 2022;20:50.
- 72 Munblit D, Nicholson T, Akrami A, *et al.* A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. *Lancet Respir Med* 2022;10:715–24.
- 73 Carlisle JB. False individual patient data and zombie randomised controlled trials submitted to Anaesthesia. *Anaesthesia* 2021;76:472–9.
- 74 Ioannidis JPA. Hundreds of thousands of zombie randomised trials circulate among us. *Anaesthesia* 2021;76:444–7.
- 75 Moi BW, Lai S, Rahim A, *et al.* Checklist to assess Trustworthiness in RANdomised Controlled Trials (TRACT checklist): concept proposal and pilot. *Res Integr Peer Rev* 2023;8:6.
- 76 Wilkinson J, Heal C, Antoniou GA, *et al.* Protocol for the development of a tool (inspect-sr) to identify problematic randomised controlled trials in systematic reviews of health interventions. *medRxiv* 2023.09.21.23295626 [Preprint] 2023.
- 77 Sterne JAC, Savović J, Page MJ, *et al.* RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:14898.
- 78 Pitre T, Kirsh S, Jassal T, *et al.* The impact of blinding on trial results: A systematic review and meta-analysis. *Cochrane Evidence Synth Methods* 2023;1:e12015.
- 79 Zeraatkar D, Pitre T, Diaz-Martinez JP, *et al.* Impact of Allocation Concealment and Blinding in Trials Addressing Treatments for COVID-19: A Methods Study. *Am J Epidemiol* 2023;192:1678–87.
- 80 Zhao Y, Shang Y, Song W, *et al.* Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *ECLINMed* 2020;25:100463.
- 81 Graham EL, Clark JR, Orban ZS, *et al.* Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers.” *Ann Clin Transl Neurol* 2021;8:1073–85.
- 82 Johnston BC, Patrick DL, Thorlund K, *et al.* Patient-reported outcomes in meta-analyses --Part 2: methods for improving interpretability for decision-makers. *Health Qual Life Outcomes* 2013;11:211.
- 83 Thorlund K, Walter SD, Johnston BC, *et al.* Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability. *Res Synth Methods* 2011;2:188–203.
- 84 Sadeghirad B, Foroutan F, Zoratti MJ, *et al.* Theory and practice of Bayesian and frequentist frameworks for network meta-analysis. *BMJ Evid Based Med* 2023;28:204–9.
- 85 Langan D, Higgins JPT, Jackson D, *et al.* A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Res Synth Methods* 2019;10:83–98.
- 86 Higgins JP TJ, Chandler J, Cumpston M. *Cochrane Handbook for Systematic Reviews of Interventions* 2nd ed. Chichester (UK): John Wiley & Sons, 2019. Available: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604>
- 87 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- 88 Mittlböck M, Heinzl H. A simulation study comparing properties of heterogeneity measures in meta-analyses. *Stat Med* 2006;25:4321–33.
- 89 Rucker G, Schwarzer G, Carpenter JR, *et al.* Undue reliance on I 2 in assessing heterogeneity may mislead. *BMC Med Res Methodol* 2008;8:79.
- 90 Mueller KF, Meerpohl JJ, Briel M, *et al.* Methods for detecting, quantifying, and adjusting for dissemination bias in meta-analysis are described. *J Clin Epidemiol* 2016;80:25–33.
- 91 Sterne JAC, Sutton AJ, Ioannidis JPA, *et al.* Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002bmj.d4002.
- 92 Chaimani A, Salanti G, Leucht S, *et al.* Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. *Evid Based Mental Health* 2017;20:88–94.
- 93 Trinquart L, Attiche N, Bafeta A, *et al.* Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials. *Ann Intern Med* 2016;164:666–73.
- 94 Mbuagbaw L, Rochweg B, Jaeschke R, *et al.* Approaches to interpreting and choosing the best treatments in network meta-analyses. *Syst Rev* 2017;6:79.
- 95 Thom H, Leahy J, Jansen JP. Network Meta-analysis on Disconnected Evidence Networks When Only Aggregate Data Are Available: Modified Methods to Include Disconnected Trials and Single-Arm Studies while Minimizing Bias. *Med Decis Making* 2022;42:906–22.
- 96 Guyatt G, Oxman AD, Akl EA, *et al.* GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
- 97 van Valkenhoef G, Dias S, Ades AE, *et al.* Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. *Res Synth Methods* 2016;7:80–93.
- 98 Ceban F, Kulzhabayeva D, Rodrigues NB, *et al.* COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. *Brain Behav Immun* 2023;111:211–29.
- 99 Fields WS, Lemak NA, Frankowski RF, *et al.* Controlled trial of aspirin in cerebral ischemia. *Circulation* 1980;62:V90–6.
- 100 The Canadian Cooperative Study Group. A Randomized Trial of Aspirin and Sulfipyrazone in Threatened Stroke. *N Engl J Med* 1978;299:53–9.
- 101 Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ* 1994;308:81–106.
- 102 Amery A, Birkenhäger W, Brixko P, *et al.* Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. 1986;4:S642–7.
- 103 Gueyffier F, Bulpitt C, Boissel J-P, *et al.* Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. *The Lancet* 1999;353:793–6.
- 104 Weisberg LA. The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. *Neurology (Ecricon)* 1993;43:27–31.
- 105 Gorelick PB, Richardson D, Kelly M, *et al.* Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. *JAMA* 2003;289:2947–57.
- 106 Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. *The Lancet* 2005;365:176–86.
- 107 Wallach JD, Sullivan PG, Trepanowski JF, *et al.* Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials. *JAMA Intern Med* 2017;177:554–60.
- 108 Schandelmaier S, Chang Y, Devasenapathy N, *et al.* A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses. *J Clin Epidemiol* 2019;113:159–67.
- 109 Donegan S, Williams L, Dias S, *et al.* Exploring Treatment by Covariate Interactions Using Subgroup Analysis and Meta-Regression in Cochrane Reviews: A Review of Recent Practice. *PLoS ONE* 2015;10:e0128804.
- 110 Kasenda B, Schandelmaier S, Sun X, *et al.* Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications. *BMJ* 2014;349:g4539.
- 111 Sun X, Briel M, Busse JW, *et al.* Credibility of claims of subgroup effects in randomised controlled trials: systematic review. *BMJ* 2012;344:e1553.
- 112 Dahabreh IJ, Hayward R, Kent DM. Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence. *Int J Epidemiol* 2016;45:dyw125.
- 113 Koopman L, van der Heijden GJMG, Hoes AW, *et al.* Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses. *Int J Technol Assess Health Care* 2008;24:358–61.
- 114 Fisher DJ, Carpenter JR, Morris TP, *et al.* Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? *BMJ* 2017;356:j573.
- 115 Schandelmaier S, Briel M, Varadhan R, *et al.* Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020;192:E901–6.

- 116 Chaimani A, Higgins JPT, Mavridis D, *et al.* Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8:e76654.
- 117 Team CDC. Network meta-analysis using frequentist methods. R Foundation for Statistical Computing; 2022.
- 118 Brignardello-Petersen R, Bonner A, Alexander PE, *et al.* Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. *J Clin Epidemiol* 2018;93:36–44.
- 119 Puhan MA, Schünemann HJ, Murad MH, *et al.* A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. *BMJ* 2014;349:g5630.
- 120 Brignardello-Petersen R, Mustafa RA, Siemieniuk RAC, *et al.* GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence. *J Clin Epidemiol* 2019;108:77–85.
- 121 Zeng L, Brignardello-Petersen R, Hultcrantz M, *et al.* GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. *J Clin Epidemiol* 2022;150:216–24.
- 122 Mouelhi Y, Jouve E, Castelli C, *et al.* How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods. *Health Qual Life Outcomes* 2020;18:136.
- 123 Schünemann HJ, Neumann I, Hultcrantz M, *et al.* GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions. *J Clin Epidemiol* 2022;150:225–42.
- 124 Zeng L, Li S-A, Yang M, *et al.* Qualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences. *J Clin Epidemiol* 2023;161:173–80.
- 125 Akl EA, Khabsa J, Iannizzi C, *et al.* Extension of the PRISMA 2020 statement for living systematic reviews (PRISMA-LSR): checklist and explanation. *BMJ* 2024;387:e079183.
- 126 Santesso N, Glenton C, Dahm P, *et al.* GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 2020;119:126–35.
- 127 Brignardello-Petersen R, Florez ID, Izcovich A, *et al.* GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. *BMJ* 2020;371:m3900.
- 128 Phillips MR, Sadeghirad B, Busse JW, *et al.* Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. *BMJ Open* 2022;12:e056400.
- 129 Akl EA, El Khoury R, Khamis AM, *et al.* The life and death of living systematic reviews: a methodological survey. *J Clin Epidemiol* 2023;156:11–21.
- 130 Murad MH, Wang Z, Chu H, *et al.* Proposed triggers for retiring a living systematic review. *BMJ Evid Based Med* 2023;28:348–52.
- 131 Siemieniuk RA, Agoritsas T, Macdonald H, *et al.* Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191.
- 132 Maurer M, Siegel JE, Firminger KB, *et al.* Lessons Learned from Developing Plain Language Summaries of Research Studies. *Health Lit Res Pract* 2021;5:e155–61.
- 133 Stoll M, Kerwer M, Lieb K, *et al.* Plain language summaries: A systematic review of theory, guidelines and empirical research. *PLoS One* 2022;17:e0268789.
- 134 World Health O. *WHO Handbook for Guideline Development*. 2nd edn. Geneva: World Health Organization, 2014.
- 135 Hill J, Bullock I, Alderson P. A Summary of the Methods That the National Clinical Guideline Centre Uses to Produce Clinical Guidelines for the National Institute for Health and Clinical Excellence. *Ann Intern Med* 2011;154:752.
- 136 Wonderling D, Sawyer L, Fenu E, *et al.* National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence. *Ann Intern Med* 2011;154:758–65.
- 137 White H, McDonald SJ, Barber B, *et al.* Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. *Med J Aust* 2022;217:368–78.
- 138 Canadian Institutes of Health Research (CIHR). Ethics guidance for developing partnerships with patients and researchers. 2020.
- 139 Prinsen CAC, Mokkink LB, Bouter LM, *et al.* COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual Life Res* 2018;27:1147–57.
- 140 Wang Z, Nayfeh T, Tetzlaff J, *et al.* Error rates of human reviewers during abstract screening in systematic reviews. *PLoS ONE* 2020;15:e0227742.
- 141 Gartlehner G, Affengruber L, Titscher V, *et al.* Single-reviewer abstract screening missed 13 percent of relevant studies: a crowd-based, randomized controlled trial. *J Clin Epidemiol* 2020;121:20–8.
- 142 Waffenschmidt S, Knelangen M, Sieben W, *et al.* Single screening versus conventional double screening for study selection in systematic reviews: a methodological systematic review. *BMC Med Res Methodol* 2019;19:132.
- 143 Buscemi N, Hartling L, Vandermeer B, *et al.* Single data extraction generated more errors than double data extraction in systematic reviews. *J Clin Epidemiol* 2006;59:697–703.
- 144 Jones AP, Remington T, Williamson PR, *et al.* High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. *J Clin Epidemiol* 2005;58:741–2.
- 145 McKiernan EC, Bourne PE, Brown CT, *et al.* How open science helps researchers succeed. *Elife* 2016;5:e16800.
- 146 Tanne JH. Covid-19: US agency launches raft of clinical trials of treatments for long covid. *BMJ* 2023;382:p1797.
- 147 Cheung a, susie e, donna I. Long covid web: pan-canadian post-covid condition research network 2022. 2022. Available: https://webapps.cihriresc.gc.ca/decisions/p/project_details.html?applid=474666&lang=en
- 148 Fisk JD, Ritvo PG, Ross L, *et al.* Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. *Clin Infect Dis* 1994;18 Suppl 1:S79–83.
- 149 Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self-rated fatigue measure: The Fatigue Assessment Scale. *J Psychosom Res* 2003;54:345–52.
- 150 Smets EM, Garssen B, Bonke B, *et al.* The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J Psychosom Res* 1995;39:315–25.
- 151 Chalder T, Berelowitz G, Pawlikowska T, *et al.* Development of a fatigue scale. *J Psychosom Res* 1993;37:147–53.
- 152 Worm-Smeitink M, Gielissen M, Bloot L, *et al.* The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. *J Psychosom Res* 2017;98:40–6.
- 153 Hayes M. Experimental development of the graphic rating method. *Psychol Bull* 1921;18:98–9.
- 154 Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. *Ann Acad Med Singap* 1994;23:129–38.
- 155 Melzack R. The McGill Pain Questionnaire: Major properties and scoring methods. *Pain* 1975;1:277–99.
- 156 Jason LA, Evans M, Porter N. The Development of a Revised Canadian Myalgic Encephalomyelitis Chronic Fatigue Syndrome Case Definition. *Am J Biochem Biotechnol* 2010;6:120–35.
- 157 Jason LA, Holtzman CS, Sunnquist M, *et al.* The development of an instrument to assess post-exertional malaise in patients with myalgic encephalomyelitis and chronic fatigue syndrome. *J Health Psychol* 2021;26:238–48.
- 158 Jaeger J. Digit Symbol Substitution Test: The Case for Sensitivity Over Specificity in Neuropsychological Testing. *J Clin Psychopharmacol* 2018;38:513–9.
- 159 Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive Function@--Adult Version. *Arch Clin Neuropsychol* 2005.
- 160 Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). *Med Care* 1992;30:473–83.
- 161 Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361–70.
- 162 HAMILTON M. The assessment of anxiety states by rating. *Br J Med Psychol* 1959;32:50–5.
- 163 HAMILTON M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;23:56:56–62.
- 164 BECK AT, WARD CH, MENDELSON M, *et al.* An inventory for measuring depression. *Arch Gen Psychiatry* 1961;4:561–71.
- 165 Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. *Chest* 1988;93:580–6.
- 166 EuroQol - a new facility for the measurement of health-related quality of life. *Health Policy* 1990;16:199–208.
- 167 The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. *Soc Sci Med* 1995;41:1403–9.